Atea Pharmaceuticals (AVIR) Payables (2019 - 2026)

Atea Pharmaceuticals' Payables history runs 8 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• In Q1 2026, Payables rose 27.87% year-over-year to $9.4 million; the TTM figure through Mar 2026 stood at $9.4 million (up 27.87% YoY), while the FY2025 annual figure was $12.9 million, up 190.38% from the prior year.
• Payables for Q1 2026 stood at $9.4 million, down from $12.9 million in the prior quarter.
• The five-year high for Payables was $21.1 million in Q1 2024, with the low at $395000.0 in Q3 2023.
• The 5-year median for Payables is $4.5 million (2024), against an average of $6.4 million.
• The sharpest annual moves came in 2022 and 2024: Payables plunged 94.96% in 2022, then jumped 2919.57% in 2024.
• Atea Pharmaceuticals' Payables stood at $2.6 million in 2022, then soared by 66.68% to $4.3 million in 2023, then grew by 4.84% to $4.5 million in 2024, then soared by 190.38% to $12.9 million in 2025, then declined by 27.03% to $9.4 million in 2026.
• Business Quant data shows AVIR's Payables at $9.4 million in Q1 2026, $12.9 million in Q4 2025, and $3.5 million in Q3 2025.